
FALL 2020 CORE FUNDING PROGRAMS

THERAPEUTIC PIPELINE PROGRAM

AN EDMOND J. SAFRA CORE PROGRAM FOR PD RESEARCH

The Michael J. Fox Foundation Grant Portal Registration Guide

All pre-proposals must be submitted through the new [MJFF Grant Portal](https://mjff.smartsimple.com/s_Login.jsp).



**Getting Started: New Users**

If you have never applied to an MJFF RFA, click the “Register Here” button.


1. Search for your organization in the “Organization Name” field. If your organization is not found, click “Add New Organization” and complete the organization registration.
2. Complete the “Contact Information” fields. Be sure to use an active email address.
3. Click the “Submit” button.
4. You will receive an email to the provided email address.
5. Follow the instructions in that email to set a password and log in to the Grant Portal.

**Getting Started: Returning Users**

If you have applied to an MJFF RFA in the past, click the “Returning User” button.

1. Input the email address associated with your MJFF account.
2. If the email you entered is in our system, you will receive an email instructing you to reset your password and log in to the Grant Portal.
3. If you do not receive an email, you may try a different email address. If you still do not receive an email, please register as a new user.

Once you have logged in to the MJFF Grant Portal, click the “Funding Opportunities” button to view open funding opportunities. Select “Therapeutic Pipeline Program Fall 2020 RFA” and proceed to start your pre-proposal.



Pre-Proposal Instructions and Requirements

Please review the instructions below before you log in to the MJFF Grant Portal. Applications will only be accepted through the MJFF Grant Portal. All pre-proposals are treated with confidentiality by The Michael J. Fox Foundation (MJFF) and our reviewers. All pre-proposals received in response to MJFF RFAs will be subjected to review and only applicants whose pre-proposals are determined to best fit criteria as defined in the RFA will be invited to submit full applications. In order to expedite the pre-proposal review process, written critiques will not be provided for those not invited to the full application stage.

**Online Application Form**

Complete the online application tabs with the following information:

* Project Information tab: Please enter basic information about your proposed project, including title, project duration, and abstract.
* Team Information tab: Please fill in required information for the Principal Investigator, including ORCID, and add other members of the team (including Co-Principal Investigators, Consultants, etc.) For each team member listed, you will need to note their first and last name, institution, position title, email, role on the project, career stage, and ORCID.
* Pre-Proposal Template tab: Complete the pre-proposal template below and upload as a pdf document.
* Confirmation tab: Please confirm your submission and input your initials.

**Please Note**

* Symbols do not transfer correctly to our online system. Spell out any symbols (e.g., alpha-synuclein) in your online form.
* Once you begin an online application, you may save and return to it before final submission. You can access it through your portal homepage under “Applications in Progress.” When ready to submit, please click “Submit” at the bottom of the application to ensure that your submission is delivered promptly to MJFF.

A notice of proposal receipt is automatically sent by email upon online submission**. If you do not receive this automatic notification within one hour of submission, please contact MJFF at** [grants@michaeljfox.org](mailto:grants@michaeljfox.org) **to check on the status of your proposal.** You should also expect an email within one week of the submission deadline notifying you of administrative review status.

FALL 2020 CORE FUNDING PROGRAMS

THERAPEUTIC PIPELINE PROGRAM

AN EDMOND J. SAFRA CORE PROGRAM FOR PD RESEARCH

#### PRE-PROPOSAL template

Please use the following template to create an executive summary of your experimental plan and upload a PDF copy with your online submission. Text should be no smaller than 11-pt font and should not exceed 2 pages***, inclusive of optional references****. You may delete the instructional text in each box below to save space.*

Principal Investigator:

Institution/Company:

Project Title:

|  |  |
| --- | --- |
| THERAPEUTIC | Describe the specific therapeutic being developed, mode of action and how the therapeutic was identified. Please identify the strengths and weaknesses of the proposed therapeutic. |
| INDICATION | Describe whether the proposed therapeutic is intended to: alter the course of disease progression, address motor or non-motor symptoms of Parkinson’s, or treat complications of therapeutic liabilities. |
| TARGET | Indicate the biological target and hypothesized mechanism and pathway for which you propose to develop a Parkinson’s disease therapeutic. If possible, also demonstrate proof of target engagement. |
| STAGE OF DEVELOPMENT | Describe the current stage of development of your proposed therapeutic (e.g., high throughput screening, hit-to-lead, lead optimization, preclinical drug candidate nomination, or clinical phases) and discuss relevant data (preclinical and/or clinical) that justifies the progression of the therapeutic to the next development stage (e.g., bioavailability, PK/PD relationships, safety). Studies to collect gaps in the data can be proposed as part of your application. |
| DEVELOPMENT PLAN | Describe and justify the proposed study(ies) that you wish to complete to move the proposed therapeutic forward. How do these studies fit into the big picture of developing a therapeutic for patients? |
| IP/PATENT LANDSCAPE | Describe any intellectual property considerations and/or restrictions that may impact how further development of the proposed therapeutic will proceed (e.g., existence of competing technologies or legal barriers to commercialization). |
| IMPACT | Indicate how a successful outcome of the proposed plan would lead to future development efforts, including ultimate goals and estimated timeline for moving the therapeutic into the next stage of development. |